Moderately Severe Hemophilia B — Clinical Trials

MONDO:00157162 active·2 recruitingLast updated: Mar 17, 2026, 3:26 PM

Trial Landscape

Moderately Severe Hemophilia B has an emerging clinical trial program, driven by gene therapy.

Recruiting

Active Trials

By Approach

Gene Therapy2

By Phase

Phase 3

Sponsor Types

Industry2

Top Sponsors

CSL Behring

Trial Locations

United States2 trials

Israel2 trials

United Kingdom1 trial

Australia1 trial

Canada1 trial

Hong Kong1 trial

Mexico1 trial

Saudi Arabia1 trial

Singapore1 trial

South Africa1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

2 Trials

Phase 3RecruitingGene Therapy

NCT06003387

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Sponsor:CSL Behring

United StatesStarted: Jan 2024Est. completion: Apr 2032Updated: Mar 2026

Phase 3Recruiting

NCT07080905

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

Sponsor:CSL Behring

United StatesStarted: Jul 2025Est. completion: Oct 2033Updated: Feb 2026

Stay informed about clinical trials for Moderately Severe Hemophilia B.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 17, 2026 at 3:26 PM